Sagimet Biosciences: Funding, Investors & Team (Sep 2026)
Sagimet Biosciences is a biopharmaceutical company in the clinical stage that specializes in the development of innovative treatments for significant diseases like NASH liver disease and specific types of cancer. They concentrate on targeting malfunctioning metabolic pathways. The company has exceptional knowledge in FASN biology and has established a series of exclusive FASN inhibitors.
Sagimet Biosciences has raised $288M across 2 funding rounds on record, the most recent an undisclosed round of $175M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Sagimet Biosciences Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Sagimet Biosciences Funding Rounds
Sagimet Biosciences raised $113M in an undisclosed round announced in Jan 2024.
2.3 years later, an undisclosed round of $175M was announced in Apr 2026.
Sagimet Biosciences Founders and Leadership Team
Contact details for the Sagimet Biosciences team: 1 of 2 have an email address on file.
Start 14-day free trial →Sagimet Biosciences Funding Compared to Other Biotechnology Startups
Sagimet Biosciences' latest round of $175M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Sagimet Biosciences in Biotechnology and San Mateo
Companies Similar to Sagimet Biosciences
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Sagimet Biosciences Funding FAQs
What does Sagimet Biosciences do?
Sagimet Biosciences is a biopharmaceutical company in the clinical stage that specializes in the development of innovative treatments for significant diseases like NASH liver disease and specific types of cancer. They concentrate on targeting malfunctioning metabolic pathways. The company has exceptional knowledge in FASN biology and has established a series of exclusive FASN inhibitors.
How much funding has Sagimet Biosciences raised?
Sagimet Biosciences has raised $288M across 2 rounds on record. The most recent is an undisclosed round of $175M announced in Apr 2026.
When did Sagimet Biosciences last raise funding?
Sagimet Biosciences' most recent funding round on record is an undisclosed round of $175M, announced in Apr 2026.
Who founded Sagimet Biosciences?
FundedIQ lists Dave Happel (Founder), Lucas Pelkmans (Founder) at Sagimet Biosciences.
Where is Sagimet Biosciences headquartered?
Sagimet Biosciences is based in San Mateo, California, United States.
How many employees does Sagimet Biosciences have?
Sagimet Biosciences is in the 11-50 employee band.
How does Sagimet Biosciences' funding compare to other Biotechnology startups?
Sagimet Biosciences' latest round of $175M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Sagimet Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Sagimet Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.